NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001996

Registered date:01/06/2009

Importance of checking exon skipping events prior to clinical trials using systemically delivered antisense morpholino in Duchenne muscular dystrophy patients

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedDuchenne muscular dystrophy
Date of first enrollment2009/06/01
Target sample size10
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)antisense morpholino

Outcome(s)

Primary OutcomeFibroblasts from DMD patients were isolated, induced to differentiate to the myogenic lineage by AdMyoD (adenoviral vectors encoding MyoD regulated by CAG Promoter) and transfected with antisense morpholinos, which were designed to induce exon 51 skipping. The exon-skipping event was analyzed by RT-PCR.
Secondary Outcome

Key inclusion & exclusion criteria

Age minimumNot applicable
Age maximum30years-old
GenderMale
Include criteria
Exclude criteriaThe patients who can not consent the protocol.

Related Information

Contact

public contact
Name
Address Japan
Telephone
E-mail kimusige@kumamoto-u.ac.jp
Affiliation Kumamoto University Graduate School Department of Child Development
scientific contact
Name Shigemi Kimura
Address 1-1-1 Honjou Kumamoto 860-0811, Japan Japan
Telephone
E-mail
Affiliation Kumamoto University Graduate School Department of Child Development,